title: [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group].
authors.affiliation: Universitäts-Hautklinik, Kiel.
authors.forename: A
authors.initials: A
authors.lastname: Hauschild
authors.forename: R
authors.initials: R
authors.lastname: Dummer
authors.forename: C
authors.initials: C
authors.lastname: Garbe
authors.forename: R
authors.initials: R
authors.lastname: Kaufmann
authors.forename: D
authors.initials: D
authors.lastname: Schadendorf
authors.forename: H P
authors.initials: HP
authors.lastname: Soyer
authors.forename: R
authors.initials: R
authors.lastname: Stadler
authors.forename: W
authors.initials: W
authors.lastname: Tilgen
mesh_terms: D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins